FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1526183483> ?p ?o ?g. }

• W1526183483 endingPage "518" @default.
• W1526183483 startingPage "508" @default.
• W1526183483 abstract "Aims To investigate the pharmacokinetics and pharmacodynamics of epirubicin and paclitaxel in combination, as well as the effects of paclitaxel and its vehicle Cremophor EL on epirubicin metabolism. Methods Twenty‐seven female patients with metastatic breast cancer received epirubicin 90 mg m −2 i.v. followed 15 min or 30 h later by a 3 h i.v. infusion of paclitaxel 175, 200 and 225 mg m −2 . Plasma concentrations of paclitaxel, epirubicin and epirubicinol were measured and the relationship between neutropenia and drug pharmacokinetics was evaluated using a sigmoid maximum effect (E max ) model. Finally, the influence of paclitaxel and Cremophor EL on epirubicin metabolism by whole blood was examined. Results An increase in epirubicinol plasma concentrations occurred after the start of the paclitaxel infusion, resulting in a significant increase in the area under the plasma concentration‐time curve (AUC) of epirubicinol (+0.5 µmol l −1 h [95% CI for the difference: 0.29, 0.71],+0.66 µmol l −1 h [95% CI for the difference: 0.47, 0.85] and +0.82 µmol l −1 h [95% CI for the difference: 0.53, 1.11] at paclitaxel doses of 175, 200 and 225 mg m −2 , respectively), compared with epirubicin followed by paclitaxel 30 h later (0.61±0.1 µmol l −1 h). A significant increase in epirubicin AUC (+0.74 µmol l −1 h [95% CI for the difference: 0.14, 1.34] and +1.09 µmol l −1 h [95% CI for the difference: 0.44, 1.74]) and decrease in drug clearance (CL TB ) (−25.35 l h −1 m −2 [95% CI for the difference: −50.18, −0.52] and −35.9 l h −1 m −2 [95% CI for the difference −63,4,−8,36]) occurred in combination with paclitaxel 200 and 225 mg m −2 with respect to the AUC (3.16±0.6 µmol l −1 h) and CL TB (74.4±28.4 l h −1 m −2 ) of epirubicin followed by paclitaxel 30 h later. An E max relationship was observed between neutropaenia and the time over which paclitaxel plasma concentrations were equal to or greater than 0.1 µmol l −1 ( tC 0.1 ). The tC 0.1 value predicted to yield a 50% decrease in neutrophil count was 7.7 h. Finally, Cremophor EL markedly inhibited the metabolism of epirubicin to epirubicinol in whole blood. Conclusions Paclitaxel/Cremophor EL affects the disposition of epirubicinol and epirubicin. Furthermore, the slope factor of the E max relationship between neutropenia and tC 0.1 of paclitaxel suggests that the drugs might also interact at the pharmacodynamic level." @default.
• W1526183483 created "2016-06-24" @default.
• W1526183483 creator A5003913815 @default.
• W1526183483 creator A5025020524 @default.
• W1526183483 creator A5034987953 @default.
• W1526183483 creator A5045454738 @default.
• W1526183483 creator A5045774368 @default.
• W1526183483 creator A5049344540 @default.
• W1526183483 creator A5068107707 @default.
• W1526183483 creator A5077498316 @default.
• W1526183483 creator A5083693387 @default.
• W1526183483 creator A5089283304 @default.
• W1526183483 date "2002-05-01" @default.
• W1526183483 modified "2023-10-18" @default.
• W1526183483 title "Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients" @default.
• W1526183483 cites W1753106810 @default.
• W1526183483 cites W1796787464 @default.
• W1526183483 cites W1836451026 @default.
• W1526183483 cites W1837236202 @default.
• W1526183483 cites W1946018534 @default.
• W1526183483 cites W1960713055 @default.
• W1526183483 cites W1970736880 @default.
• W1526183483 cites W1988234658 @default.
• W1526183483 cites W1998276910 @default.
• W1526183483 cites W2012393101 @default.
• W1526183483 cites W2018835423 @default.
• W1526183483 cites W2023174165 @default.
• W1526183483 cites W2023476712 @default.
• W1526183483 cites W2046869918 @default.
• W1526183483 cites W2050062541 @default.
• W1526183483 cites W2062366998 @default.
• W1526183483 cites W2068629038 @default.
• W1526183483 cites W2070147796 @default.
• W1526183483 cites W2070301035 @default.
• W1526183483 cites W2133003338 @default.
• W1526183483 cites W2143176991 @default.
• W1526183483 cites W2154985964 @default.
• W1526183483 cites W2160207820 @default.
• W1526183483 cites W2165982968 @default.
• W1526183483 cites W2167244629 @default.
• W1526183483 cites W2171228726 @default.
• W1526183483 cites W2175322882 @default.
• W1526183483 cites W2203687533 @default.
• W1526183483 cites W2228702773 @default.
• W1526183483 cites W2232368099 @default.
• W1526183483 cites W2242824667 @default.
• W1526183483 cites W2268597691 @default.
• W1526183483 cites W2334195749 @default.
• W1526183483 cites W2437404060 @default.
• W1526183483 doi "https://doi.org/10.1046/j.1365-2125.2002.01579.x" @default.
• W1526183483 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1874362" @default.
• W1526183483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11994057" @default.
• W1526183483 hasPublicationYear "2002" @default.
• W1526183483 type Work @default.
• W1526183483 sameAs 1526183483 @default.
• W1526183483 citedByCount "43" @default.
• W1526183483 countsByYear W15261834832012 @default.
• W1526183483 countsByYear W15261834832013 @default.
• W1526183483 countsByYear W15261834832014 @default.
• W1526183483 countsByYear W15261834832015 @default.
• W1526183483 countsByYear W15261834832016 @default.
• W1526183483 countsByYear W15261834832017 @default.
• W1526183483 countsByYear W15261834832018 @default.
• W1526183483 countsByYear W15261834832020 @default.
• W1526183483 countsByYear W15261834832021 @default.
• W1526183483 countsByYear W15261834832022 @default.
• W1526183483 countsByYear W15261834832023 @default.
• W1526183483 crossrefType "journal-article" @default.
• W1526183483 hasAuthorship W1526183483A5003913815 @default.
• W1526183483 hasAuthorship W1526183483A5025020524 @default.
• W1526183483 hasAuthorship W1526183483A5034987953 @default.
• W1526183483 hasAuthorship W1526183483A5045454738 @default.
• W1526183483 hasAuthorship W1526183483A5045774368 @default.
• W1526183483 hasAuthorship W1526183483A5049344540 @default.
• W1526183483 hasAuthorship W1526183483A5068107707 @default.
• W1526183483 hasAuthorship W1526183483A5077498316 @default.
• W1526183483 hasAuthorship W1526183483A5083693387 @default.
• W1526183483 hasAuthorship W1526183483A5089283304 @default.
• W1526183483 hasBestOaLocation W15261834831 @default.
• W1526183483 hasConcept C111113717 @default.
• W1526183483 hasConcept C112705442 @default.
• W1526183483 hasConcept C121608353 @default.
• W1526183483 hasConcept C126322002 @default.
• W1526183483 hasConcept C2776694085 @default.
• W1526183483 hasConcept C2777292972 @default.
• W1526183483 hasConcept C2780835546 @default.
• W1526183483 hasConcept C530470458 @default.
• W1526183483 hasConcept C71924100 @default.
• W1526183483 hasConcept C76318530 @default.
• W1526183483 hasConcept C98274493 @default.
• W1526183483 hasConceptScore W1526183483C111113717 @default.
• W1526183483 hasConceptScore W1526183483C112705442 @default.
• W1526183483 hasConceptScore W1526183483C121608353 @default.
• W1526183483 hasConceptScore W1526183483C126322002 @default.
• W1526183483 hasConceptScore W1526183483C2776694085 @default.
• W1526183483 hasConceptScore W1526183483C2777292972 @default.
• W1526183483 hasConceptScore W1526183483C2780835546 @default.
• W1526183483 hasConceptScore W1526183483C530470458 @default.

• next